The company that makes Wegovy — and what that means for you

Why the manufacturer's identity shapes what's legal to dispense in the UK

Novo Nordisk is headquartered in Bagsværd, Denmark, and is one of the world's largest pharmaceutical companies by market capitalisation. Its focus has always been narrow: diabetes, obesity, and related conditions. That specialisation matters because it explains the depth of evidence behind semaglutide. The company ran the long SCALE trial programme for semaglutide 2.4mg in weight management (STEP 1 alone enrolled nearly 2,000 adults) before Wegovy received its first UK marketing authorisation.

In the UK, a medicine's manufacturer holds the marketing authorisation granted by the MHRA. Only medicines supplied through the authorised supply chain (from Novo Nordisk's approved distributors to licensed pharmacies) are covered by that authorisation. That is the chain a GPhC-registered pharmacy like ours at nume operates within. Sellers offering semaglutide without that provenance are outside it, regardless of what they claim on the label.

The MHRA has issued repeated warnings about counterfeit GLP-1 pens circulating online, including fake pens that have contained insulin. Enforcement through 2025 led to seizures of roughly 20 million doses of illegally traded weight-loss medicines. The manufacturer's identity only protects you when you access the product through a pharmacy you can verify on the GPhC register.

Semaglutide under different brand names, the distinction worth knowing

Novo Nordisk markets semaglutide under several names in the UK, and they are not interchangeable. Semaglutide as a molecule appears in Ozempic (0.5mg and 1mg weekly injection, licensed for type 2 diabetes), Rybelsus (oral tablets, 3mg/7mg/14mg, also licensed for type 2 diabetes), and Wegovy (injection 0.25mg to 2.4mg, now up to 7.2mg, and the new 25mg oral tablet, both licensed for weight management).

The MHRA licences each of these separately. Ozempic's authorisation covers blood glucose control; it has never held a weight-management licence in the UK. Prescribing Ozempic for weight loss is off-label, and the MHRA and NHS England have explicitly steered away from this. If you are looking at what Wegovy's manufacturer authorises for weight loss, the answer is Wegovy specifically, not Ozempic, not Rybelsus.

The oral Wegovy tablet, approved on 11 June 2026, uses an absorption enhancer called SNAC to allow semaglutide to cross the gut lining. It is taken once daily on an empty stomach with a small amount of plain water, at least 30 minutes before any food or drink. No refrigeration is required, a practical advantage the injection pen does not share. You can read more about the full range of available treatments on our weight-loss treatment overview.

What Novo Nordisk's approvals mean for your choice between injection and tablet

The decision between Wegovy injection and Wegovy tablet is a clinical one, made with a prescriber who knows your history. That said, the manufacturer's trial data gives you a factual starting point. The STEP 1 trial (68 weeks, semaglutide 2.4mg weekly injection) reported an average body-weight reduction of around 15%, as covered in the NEJM publication of STEP 1. The 7.2mg injection, approved by the MHRA in April 2026, pushed reported averages to roughly 20.7% over 72 weeks. The oral tablet's phase-3 trial (OASIS 4, 64 weeks) reported an average weight loss of around 13.6%, or approximately 17% among participants who adhered fully to the regimen.

None of those figures translate directly to an individual outcome. Weight loss on any GLP-1 medicine depends on adherence, diet, activity, and factors a prescriber considers during assessment. Novo Nordisk's job was to demonstrate safety and efficacy across a trial population; a prescriber's job is to work out whether you are in the part of that population who stands to benefit. You can read about the Wegovy dosing schedule to understand how titration works, though the actual pacing of your doses is always guided by your prescriber.

On cost: Novo Nordisk sets the list price, and private providers build their pricing on top of supply costs, clinical infrastructure, and service levels. A realistic sense of what private Wegovy costs in the UK is set out on the Wegovy prices page. Prices vary by dose and provider; be sceptical of anything priced far below the market, particularly from sources that cannot demonstrate a GPhC registration. If you have questions about how our prescribers work or who reviews your consultation, our clinical team page gives you a direct look.

Accessing Wegovy through a regulated route in the UK

If you are considering Wegovy and have done even a small amount of research, you have probably found that the NHS route involves waiting lists and strict eligibility criteria under NICE's guidance (TA875), which limits NHS Wegovy to specialist weight management services. Private prescription is the alternative for people who meet the licensed eligibility criteria but do not want to wait, or do not qualify under NHS thresholds.

The NHS's own guidance on weight-management injections is a useful reference for understanding what clinical support looks like alongside a GLP-1 medicine. For anyone interested in a private route, the first step is a clinical consultation, not a purchase. A prescriber reviews your BMI, weight-related conditions, medical history, and any medicines you take before any prescription is issued. That applies whether your prescriber is in an NHS clinic or at a regulated online pharmacy.

Payday orders, Monday morning starts, pre-holiday top-ups, the timing people choose to begin treatment tends to reflect real life rather than a clinical calendar. Whatever the moment, the consultation itself takes a few minutes and is reviewed the same day by a named prescriber. Side effects are part of any honest conversation about starting treatment, and patients sometimes ask about things like dry lips that can occur with Wegovy, which is worth being aware of before you begin. If you want to check whether Wegovy is suitable for you, start your free consultation and a prescriber will assess your eligibility.